ENTA Enanta Pharmaceuticals, Inc. Common Stock

Data is currently not available
ENTA
Data is currently not available
Access your previously viewed quotes
Your previously viewed symbols will appear here as you browse the site.
Previously Viewed
  • Data is currently not available
Quotes and Chart Key Data News Options Profile Filings - Ownership

ENTA

See real-time trades
SELECT THE TIMEFRAME :
Data is currently not available
Previous
Close  
See Pre-Market Trading See After-Hours Trading

Links for Quotes and Charts

Summary Data

Data is currently not available

Links for Key Data

Earnings Per Share

Estimated Reported
Data is currently not available
Estimated EPS 1.00
Reported EPS: 1.00
SEE ALL REVENUE AND Earnings Per Share

Dividend History

  • ENTA Ex-Dividend Date  
  • ENTA Dividend Yield  %
  • ENTA Annual Dividend $ 
  • ENTA Payout Ratio  %
Data is currently not available
 
   
See Full Dividend History

Short Interest

Data is currently not available
 
   
See Full Short Interest History

News Quick Links

Published
Nov 22, 2019
Markets

Enanta Pharmaceuticals' Q4 Results Pulled Down by AbbVie's Sinking HCV Sales

Published
Nov 22, 2019
Published
Nov 21, 2019
Markets

Enanta Pharmaceuticals Inc (ENTA) Q4 2019 Earnings Call Transcript

Published
Nov 21, 2019
Published
Nov 20, 2019
Markets

Commit To Buy Enanta Pharmaceuticals At $55, Earn 16.5% Annualized Using Options

Published
Nov 20, 2019
Published
Sep 26, 2019
Markets

AbbVie Receives FDA Approval Of MAVYRET

Published
Sep 26, 2019
See More
See All News

News

Published
Nov 21, 2019

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2019

Published
Nov 21, 2019
Published
Nov 11, 2019

Enanta Pharmaceuticals Announces Poster Presentations at The Liver Meeting® 2019

Published
Nov 11, 2019
Published
Nov 5, 2019

Enanta Pharmaceuticals to Host Conference Call on November 21 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2019

Published
Nov 5, 2019
Published
Oct 21, 2019

Enanta Pharmaceuticals to Present at the 2019 Wolfe Research Healthcare Conference

Published
Oct 21, 2019
Published
Oct 3, 2019

New Data from Enanta’s Phase 2a Human Challenge Study of EDP-938 for RSV Demonstrates Highly Statistically Significant Reductions (p<0.001) in Total Symptom Score, Mucus Weight and RSV Viral Load as Measured by RT-PCR Assay and by Plaque Assay

Published
Oct 3, 2019
Published
Sep 25, 2019

Enanta Announces Positive Results of ARGON-1 Study of its lead FXR Agonist, EDP-305, for the Treatment of NASH

Published
Sep 25, 2019
Published
Sep 10, 2019

New Data from Enanta’s Phase 2a Human Challenge Study of EDP-938 for RSV to be Presented at IDWeek™ 2019

Published
Sep 10, 2019
Published
Aug 2, 2019

AbbVie's MAVIRET™ (glecaprevir/pibrentasvir) Approved by European Commission to Shorten Treatment Duration to Eight Weeks for Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis

Published
Aug 2, 2019
See All Press Releases

Published

Published

ENTA Analyst Ratings

Data is currently not available
Consensus  

 

See all analyst research

Forecasts

SELECT THE TIMEFRAME :
Data is currently not available
 
   

Option Chain

Data is currently not available
 
 
 
 
 
 
 
See full OPTION CHAIN history
Data is currently not available

Key Executives
Name Title
Address: Phone:
Fundamentals

Ownership and SEC Filings

Historical

Download Data
Data is currently not available
 
   
See Full Historical Data See Historical NOCP

Active stocks by Dollar Volume

AMZN

Data is currently not available
AAPL

Data is currently not available
TSLA

Data is currently not available
INTC

Data is currently not available

Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these sessions may offer less liquidity and inferior prices. Stock prices may also move more quickly in this environment. Investors who anticipate trading during these times are strongly advised to use limit orders.

  • Real-time Data is provided using Nasdaq Last Sale Data